Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Embracing Future HoldingsSGX:8YY -7.14% EV-to-FCF is -36.02 as of Jul. 25, 2026. The stock has 5 warning signs investors should review. Among 100 Medical Diagnostics & Research companies, Embracing Future Holdings ranks worse than 999999% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Embracing Future Holdings's Enterprise Value is S$69.45 Mil.
Embracing Future Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was S$-1.93 Mil. Therefore, Embracing Future Holdings's EV-to-FCF for today is -36.02.
The historical rank and industry rank for Embracing Future Holdings's EV-to-FCF or its related term are showing as below:
SGX:8YY'
s EV-to-FCF Range Over the Past 10 Years
Min: -79.32 Med: -5.33 Max: -0.93
Current: -36.02
During the past 11 years, the highest EV-to-FCF of Embracing Future Holdings was -0.93. The lowest was -79.32. And the median was -5.33.
SGX:8YY's EV-to-FCF is ranked worse than 100% of 100
companies
in the Medical Diagnostics & Research industry
Industry Median: 26.57
vs SGX:8YY: -36.02
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Embracing Future Holdings's PE Ratio (TTM) for today is calculated as:
Embracing Future Holdings's share price for today is S$0.039.
Embracing Future Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was S$-0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Embracing Future Holdings EV-to-FCF Related Terms
Embracing Future Holdings EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Embracing Future Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embracing Future Holdings EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Embracing Future Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Embracing Future Holdings's EV-to-FCF falls into.
Embracing Future Holdings's current Enterprise Value is S$69.45 Mil.
Embracing Future Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was S$-1.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Embracing Future Holdings (SGX:8YY) has a EV-to-FCF of -36.02 as of Jul. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Embracing Future Holdings and its competitors. According to the industry distribution chart, Embracing Future Holdings ranks #999999 out of 100 companies in the Medical Diagnostics & Research industry.
Is Embracing Future Holdings' EV-to-FCF too high?
Embracing Future Holdings' current EV-to-FCF is -36.02. Based on the distribution chart, Embracing Future Holdings ranks #999999 out of 100 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Embracing Future Holdings' EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Embracing Future Holdings ranks #999999 out of 100 companies for EV-to-FCF. This places Embracing Future Holdings in the lower half of its industry. The industry median EV-to-FCF is 26.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 26.57, based on 100 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Embracing Future Holdings and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 26.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embracing Future Holdings's current EV-to-FCF is -36.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embracing Future Holdings stock overvalued right now?
Embracing Future Holdings (SGX:8YY) has a current EV-to-FCF of -36.02. The current EV-to-FCF is -36.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Embracing Future Holdings (SGX:8YY), the current EV-to-FCF is -36.02 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Embracing Future Holdings Ltd is engaged in technology development, technology transfer, marketing, sales, and distribution of biomedical technology, life, and medicine science-related products and services, and investment holding. The company's business segments are: Cancer, Infectious Diseases, E-sports, Advertising, and Corporate. The company generates the majority of its revenue from the E-sports segment, which involves identifying and assessing potential collaboration partners, technology, digital platforms, products, and services related to E-Sports. Its operations are spread across Singapore, Japan, China, Europe, Hong Kong, Thailand, Malaysia, and other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:8YY has been successfully added to your 
